Remove Behavioural Health Remove Development Remove Medicine Remove Trials
article thumbnail

Sanofi forges $30m alliance with digital health firm DarioHealth

pharmaphorum

Originally set up with a focus on diabetes, Dario has added capabilities in hypertension, weight management, and musculoskeletal and behavioural health in the intervening years, for example by acquiring musculoskeletal wearable company Upright Technologies and digital behavioural health specialist wayForward last year.

article thumbnail

Applied Virtual Reality in Healthcare: A comprehensive book on medical XR

pharmaphorum

Still, it can be challenging to acquire a complete picture of how this technology is used overall in medicine. “I Walter says pharma can wield many of the book’s insights to improve its portfolios and help advance immersive technology in medicine. How pharma can leverage XR.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What we’re expecting in 2021, and beyond…

pharmaphorum

From telehealth to digital trials, customer engagement to healthcare data, Healthware Group outlines the key trends that are expected to shake up digital health this year. Mental health worsens – digital tools continue to fill the gap. Clinical trials get more and more digitalised.

article thumbnail

5 Telehealth Providers to Rely on During Covid-19

Find Me Cure

Valley Health is a Telehealth service provider that also shows commitment to fighting the pandemic by offering a Covid-19 assessment. Their regular services include behavioural health, MAT, family medicine, internal medicine, and paediatrics. Teladoc Health. Their locations are in West Virginia.

Doctors 69
article thumbnail

Drug discovery predictions: Analysis and insight 

Drug Discovery World

Here, Thomas reflects specifically on Anita Cooper’s prediction relating to the importance of clinical trials. . Following the launch of Protas, DDW spoke with Protas Chief Executive, Professor Sir Martin Landray, who echoed Cooper’s emphasis on the importance of clinical trial design.